{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:43:22Z","timestamp":1788507802184,"version":"build-2803163510"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Recent studies have challenged the notion that patients with brain metastasis (BM) or leptomeningeal metastasis (LM) should be excluded from systemic therapy clinical trials. This scoping study summarizes the BM\/LM clinical studies published between 2010 and 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>MEDLINE, CINAHL, CAB Abstracts, PsycINFO, Cochrane Library, HINARI, International Pharmaceutical Abstracts, PubMed, Scopus, Web of Science, and EMBASE electronic databases were searched on June 21, 2021. An updated search was performed on February 21, 2023. Eligible studies investigated a therapeutic intervention in solid tumor patients with BM and\/or LM and reported a patient outcome. Extracted study-level data, including study type, publication date, geographical location, number of BM\/LM patients in the study, primary tumor type, and type of therapeutic intervention, were collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>4921 unique studies were eligible for analysis. The key finding is that BM\/LM clinical research is expanding globally, both in observational studies and clinical trials. Despite the shift over time toward a higher proportion of systemic therapy trials, the majority still do not include patients with symptomatic disease and lack reporting of BM\/LM-specific endpoints. Globally, there has been a trend to more international collaboration in BM\/LM clinical studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our analysis of the BM\/LM literature charts the evolving landscape of studies involving this previously excluded population. Given the increasing clinical research activity, particularly involving late-stage systemic therapy trials, it is imperative that due consideration is given to the intracranial activity of new investigational agents. Wider adoption of standardized reporting of intracranial-specific endpoints will facilitate the evaluation of relative intracranial efficacy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noae140","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T17:35:58Z","timestamp":1722620158000},"page":"2193-2207","source":"Crossref","is-referenced-by-count":3,"title":["BMScope: A scoping review to chart the evolving clinical study landscape in brain and leptomeningeal metastasis"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4159-8697","authenticated-orcid":false,"given":"Vinton W T","family":"Cheng","sequence":"first","affiliation":[{"name":"Leeds Institute of Medical Research, St James\u2019s University Hospital, University of Leeds , Leeds ,","place":["UK"]},{"name":"Department of Cancer and Genomic Sciences, University of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Heywood","sequence":"additional","affiliation":[{"name":"Department of Oncology, St James\u2019s University Hospital, Leeds Teaching Hospitals NHS Trust , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasheed","family":"Zakaria","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Cancer Medicine, University of Liverpool , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Burger","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London ,","place":["UK"]},{"name":"Department of Oncology, St James\u2019s University Hospital, Leeds Teaching Hospitals NHS Trust , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Zucker","sequence":"additional","affiliation":[{"name":"Leeds Institute of Data Analytics, University of Leeds , Leeds ,","place":["UK"]},{"name":"Department of Oncology, St James\u2019s University Hospital, Leeds Teaching Hospitals NHS Trust , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddarth","family":"Kannan","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Central Lancashire , Preston ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Alifian Remifta","family":"Putra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,\u00a0Cipto Mangunkusumo Hospital , Jakarta ,","place":["Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-3797","authenticated-orcid":false,"given":"Amanda","family":"Fitzpatrick","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Centre, King\u2019s College London , London ,","place":["UK"]},{"name":"Department of Medical Oncology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Doherty","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sanghera","sequence":"additional","affiliation":[{"name":"Department of Oncology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Jenkinson","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Pharmacology, University of Liverpool , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Institute of Systems, Molecular and Integrative Biology, University of Liverpool , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"issue":"4","key":"2024121020413781900_CIT0001","doi-asserted-by":"crossref","first-page":"e20212121","DOI":"10.1084\/jem.20212121","article-title":"The anatomic basis of leptomeningeal metastasis","volume":"221","author":"Freret","year":"2024","journal-title":"J Exp Med."},{"issue":"11","key":"2024121020413781900_CIT0002","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"2024121020413781900_CIT0003","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11060-019-03186-z","article-title":"Health-related quality of life of patients with brain metastases selected for stereotactic radiosurgery","volume":"143","author":"Verhaak","year":"2019","journal-title":"J Neurooncol."},{"key":"2024121020413781900_CIT0004","doi-asserted-by":"crossref","first-page":"806344","DOI":"10.3389\/fneur.2022.806344","article-title":"Quality of life and role of palliative and supportive care for patients with brain metastases and caregivers: a review","volume":"13","author":"Wu","year":"2022","journal-title":"Front Neurol."},{"issue":"6","key":"2024121020413781900_CIT0005","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024121020413781900_CIT0006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep."},{"issue":"2","key":"2024121020413781900_CIT0007","doi-asserted-by":"crossref","first-page":"e000024","DOI":"10.1136\/esmoopen-2015-000024","article-title":"Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers","volume":"1","author":"Berghoff","year":"2016","journal-title":"ESMO Open"},{"issue":"11","key":"2024121020413781900_CIT0008","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/sj.bjc.6605373","article-title":"Brain metastases admissions in Sweden between 1987 and 2006","volume":"101","author":"Smedby","year":"2009","journal-title":"Br J Cancer."},{"issue":"1","key":"2024121020413781900_CIT0009","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1038\/s41598-021-87357-x","article-title":"Radiotherapy for brain metastasis and long-term survival","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep."},{"issue":"1","key":"2024121020413781900_CIT0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2013.05.002","article-title":"Stereotactic radiosurgery in the treatment of brain metastases: the current evidence","volume":"40","author":"Lippitz","year":"2014","journal-title":"Cancer Treat Rev."},{"issue":"Suppl 5","key":"2024121020413781900_CIT0011","first-page":"v4","article-title":"Surgical advances in the management of brain metastases","volume":"3","author":"Ng","year":"2021","journal-title":"Neurooncol Adv."},{"issue":"6","key":"2024121020413781900_CIT0012","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","article-title":"The blood","volume":"13","author":"Deeken","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2024121020413781900_CIT0013","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/neuonc\/noz246","article-title":"Exclusion of patients with brain metastases from cancer clinical trials","volume":"22","author":"Patel","year":"2020","journal-title":"Neuro Oncol"},{"issue":"33","key":"2024121020413781900_CIT0014","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol."},{"issue":"8","key":"2024121020413781900_CIT0015","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med."},{"issue":"7","key":"2024121020413781900_CIT0016","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med."},{"issue":"10","key":"2024121020413781900_CIT0017","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(\u2606)","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann Oncol."},{"issue":"1","key":"2024121020413781900_CIT0018","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol."},{"issue":"13","key":"2024121020413781900_CIT0019","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.18.01511","article-title":"TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases","volume":"37","author":"Freedman","year":"2019","journal-title":"J Clin Oncol."},{"issue":"10","key":"2024121020413781900_CIT0020","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1016\/S1470-2045(13)70308-5","article-title":"Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group","volume":"14","author":"Lin","year":"2013","journal-title":"Lancet Oncol."},{"issue":"18","key":"2024121020413781900_CIT0021","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.ejca.2012.07.002","article-title":"Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC brain metastases strategic meeting 2012","volume":"48","author":"Preusser","year":"2012","journal-title":"Eur J Cancer."},{"key":"2024121020413781900_CIT0022","author":"World Health Organization","year":"2020"},{"issue":"12","key":"2024121020413781900_CIT0023","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2024121020413781900_CIT0024","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijrobp.2017.04.041","article-title":"Vorinostat and concurrent stereotactic radiosurgery for non-small cell lung cancer brain metastases: a phase 1 dose escalation trial","volume":"99","author":"Choi","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"34","key":"2024121020413781900_CIT0025","doi-asserted-by":"crossref","first-page":"56199","DOI":"10.18632\/oncotarget.14147","article-title":"A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors","volume":"8","author":"Deutsch","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2024121020413781900_CIT0026","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11060-016-2275-x","article-title":"Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study","volume":"131","author":"Chabot","year":"2017","journal-title":"J Neurooncol."},{"issue":"3","key":"2024121020413781900_CIT0027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canrad.2016.02.008","article-title":"Radiation-enhancing effect of sodium glycididazole in patients suffering from non-small cell lung cancer with multiple brain metastases: a randomized, placebo-controlled study","volume":"20","author":"Zeng","year":"2016","journal-title":"Cancer Radiother."},{"issue":"2","key":"2024121020413781900_CIT0028","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tranon.2015.12.003","article-title":"Whole brain radiotherapy and RRx-001: two partial responses in radioresistant melanoma brain metastases from a phase I\/II clinical trial A TITE-CRM Phase I\/II Clinical Trial","volume":"9","author":"Kim","year":"2016","journal-title":"Transl Oncol."},{"issue":"1","key":"2024121020413781900_CIT0029","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13063-023-07277-1","article-title":"Quantifying the impact of the COVID-19 pandemic on clinical trial screening rates over time in 37 countries","volume":"24","author":"McDonald","year":"2023","journal-title":"Trials"},{"key":"2024121020413781900_CIT0030","doi-asserted-by":"crossref","first-page":"812370","DOI":"10.3389\/fmed.2021.812370","article-title":"COVID-19 pandemic and trends in clinical trials: a multi-region and global perspective","volume":"8","author":"Nishiwaki","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2024121020413781900_CIT0031","first-page":"19","article-title":"Impact of the COVID-19 pandemic on non-COVID-19 clinical trials","volume":"9","author":"Audisio","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"2024121020413781900_CIT0032","author":"DESA U","year":"2023"},{"issue":"3","key":"2024121020413781900_CIT0033","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3816\/CLC.2010.n.022","article-title":"Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study","volume":"11","author":"Chua","year":"2010","journal-title":"Clin Lung Cancer."},{"key":"2024121020413781900_CIT0034","doi-asserted-by":"crossref","first-page":"11795549221079185","DOI":"10.1177\/11795549221079185","article-title":"Whole-brain radiotherapy combined with anlotinib for multiple brain metastases from non-small cell lung cancer without targetable driver mutation: a single-arm, phase II study","volume":"16","author":"Liu","year":"2022","journal-title":"Clin Med Insights Oncol"},{"key":"2024121020413781900_CIT0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2022.03.016","article-title":"Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases","volume":"170","author":"Palmer","year":"2022","journal-title":"Radiother Oncol."},{"issue":"8","key":"2024121020413781900_CIT0036","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"2024121020413781900_CIT0037","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol."},{"issue":"8","key":"2024121020413781900_CIT0038","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10055","key":"2024121020413781900_CIT0039","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","article-title":"Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet."},{"issue":"9","key":"2024121020413781900_CIT0040","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"2024121020413781900_CIT0041","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med."},{"issue":"10","key":"2024121020413781900_CIT0042","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med."},{"issue":"21","key":"2024121020413781900_CIT0043","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med."},{"issue":"7","key":"2024121020413781900_CIT0044","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"2024121020413781900_CIT0045","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol."},{"issue":"9","key":"2024121020413781900_CIT0046","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med."},{"issue":"19","key":"2024121020413781900_CIT0047","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2217\/fon-2019-0180","article-title":"ATTAIN: phase III study of etirinotecan pegol versus treatment of physician\u2019s choice in patients with metastatic breast cancer and brain metastases","volume":"15","author":"Tripathy","year":"2019","journal-title":"Future Oncol."},{"issue":"8","key":"2024121020413781900_CIT0048","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(23)00292-9","article-title":"Retraction and republication-TRICOTEL: defining symptomatic brain metastases in clinical trials","volume":"24","author":"Dummer","year":"2023","journal-title":"Lancet Oncol."},{"issue":"12","key":"2024121020413781900_CIT0049","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S1470-2045(23)00334-0","article-title":"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study","volume":"24","author":"Dummer","year":"2023","journal-title":"Lancet Oncol."},{"issue":"16","key":"2024121020413781900_CIT0050","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.23.01777","article-title":"Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials: time series analyses for 2012","volume":"42","author":"Xiao","year":"2024","journal-title":"J Clin Oncol."},{"key":"2024121020413781900_CIT0051","volume-title":"Cancer Clinical Trial Eligibility Criteria: Brain Metastases","author":"FDA US","year":"2020"},{"issue":"33","key":"2024121020413781900_CIT0052","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1200\/JCO.2017.74.0761","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group","volume":"35","author":"Lin","year":"2017","journal-title":"J Clin Oncol."},{"issue":"4","key":"2024121020413781900_CIT0053","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/neuonc\/noz201","article-title":"Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer","volume":"22","author":"Le Rhun","year":"2020","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024121020413781900_CIT0054","doi-asserted-by":"crossref","first-page":"101624","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"2024121020413781900_CIT0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000447043","article-title":"Increasing access to clinical trials and innovative therapy for teenagers and young adults with cancer","volume":"43","author":"Gaspar","year":"2016","journal-title":"Prog Tumor Res"},{"issue":"6","key":"2024121020413781900_CIT0056","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1586\/17512433.2015.1088382","article-title":"Clinical trial design for rare cancers: why a less conventional route may be required","volume":"8","author":"Panageas","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"2024121020413781900_CIT0057","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB Randomized Clinical Trial","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"issue":"5","key":"2024121020413781900_CIT0058","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-20-2701","article-title":"FDA approval summary: tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer","volume":"27","author":"Shah","year":"2021","journal-title":"Clin Cancer Res."},{"key":"2024121020413781900_CIT0059","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.breast.2022.03.013","article-title":"Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: a review","volume":"63","author":"Bhogal","year":"2022","journal-title":"Breast"},{"issue":"6","key":"2024121020413781900_CIT0060","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol."},{"issue":"5","key":"2024121020413781900_CIT0061","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/neuonc\/noz024","article-title":"The RANO leptomeningeal metastasis group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal","volume":"21","author":"Le Rhun","year":"2019","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024121020413781900_CIT0062","doi-asserted-by":"crossref","first-page":"CNS28","DOI":"10.2217\/cns-2018-0007","article-title":"Use of the response assessment in neuro-oncology (RANO) criteria in clinical trials and clinical practice","volume":"8","author":"Chukwueke","year":"2019","journal-title":"CNS Oncol"},{"issue":"10","key":"2024121020413781900_CIT0063","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/neuonc\/noac118","article-title":"Brain metastases: a Society for Neuro-Oncology (SNO) consensus review on current management and future directions","volume":"24","author":"Aizer","year":"2022","journal-title":"Neuro Oncol"},{"issue":"Suppl 1","key":"2024121020413781900_CIT0064","doi-asserted-by":"crossref","first-page":"e000112","DOI":"10.1136\/esmoopen-2016-000112","article-title":"Erlotinib intercalating pemetrexed\/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668)","volume":"2","author":"Yang","year":"2017","journal-title":"ESMO Open"},{"key":"2024121020413781900_CIT0065","doi-asserted-by":"crossref","first-page":"e2100522","DOI":"10.1200\/PO.21.00522","article-title":"Phase II Study of Lorlatinib in patients with anaplastic lymphoma kinase-positive lung cancer and CNS-specific relapse","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"2024121020413781900_CIT0066","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S1470-2045(17)30693-9","article-title":"Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases Working Group","volume":"19","author":"Camidge","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"2024121020413781900_CIT0067","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"2024121020413781900_CIT0068","doi-asserted-by":"crossref","first-page":"858577","DOI":"10.3389\/fmolb.2022.858577","article-title":"Identifying topics and evolutionary trends of literature on brain metastases using latent dirichlet allocation","volume":"9","author":"Chen","year":"2022","journal-title":"Front Mol Biosci"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae140\/59249180\/noae140.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/12\/2193\/60964205\/noae140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/12\/2193\/60964205\/noae140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T21:38:55Z","timestamp":1733866735000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/26\/12\/2193\/7726356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":68,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,8,2]]},"published-print":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae140","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,8,2]]}}}